Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | DPYD | Q12882 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17162074 | 0.74 | PKM (0.51) | MAPTALDH1A1LMNACYP19A1TSHR | |
| SCHEMBL30432561 | 0.74 | PKM (0.51) | MAPTALDH1A1LMNACYP19A1TSHR | |
| SCHEMBL17169678 | 0.72 | MAPT (0.45) | MAPTALDH1A1LMNACYP19A1TSHR | |
| SCHEMBL5788299 | 0.72 | MAPT (0.52) | MAPTALDH1A1LMNACYP19A1TSHR | |
| SCHEMBL17169684 | 0.67 | ALDH1A1 (0.43) | MAPTALDH1A1LMNACYP19A1TSHR | |
| SCHEMBL17169680 | 0.65 | MAPT (0.38) | MAPTALDH1A1LMNACYP19A1TSHR | |
| SCHEMBL17169693 | 0.65 | PKM (0.39) | MAPTALDH1A1LMNACYP19A1TSHR | |
| SCHEMBL17169686 | 0.65 | PKM (0.44) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL249289 | 0.64 | MAPT (1.00) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL3646 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716315-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716315-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716315-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-06 | — | — | US | disclosed |
| US-7320991-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320991-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320991-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070293519-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2007-12-20 | — | — | US | disclosed |
| US-20070293519-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2007-12-20 | — | — | US | disclosed |
| US-20070293519-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2007-12-20 | — | — | US | disclosed |
| US-20040077685-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2004-04-22 | — | — | US | disclosed |
| EP-1389203-A2 | ANALOGS OF THALIDOMIDE AS POTENTIAL ANGIOGENESIS INHIBITORS | The Governement of the United States of America, represented by The Secretary Department of Health and Human services (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002068414-A2 | ANALOGS OF THALIDOMIDE AS POTENTIAL ANGIOGENESIS INHIBITORS | THE GOVERNEMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077685-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | FLT4, TEK, VEGFA | MAPT 1413/4885ALDH1A1 1237/4885LMNA 4787/4885 |
| US-20070293519-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | FLT4, TEK, VEGFA | MAPT 1167/4885ALDH1A1 1243/4885LMNA 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.